Leidsin ühe sellise minu meelest huvitava ettevõtte.Tegemist on toidulisandite tootjaga (kui ma asjast õieti olen aru saanud)Kahjuks väga põhjalikult veel analüüsida ei oska,kuid nagu ma aru saan on tegemist ettevõttega,mis kahjumist välja hakkab ronima? Paar päeva tagasi panin omale jälgimisnimekirja. Kauples veel paar päeva tagasi oma põhja juures (ˇ2 NOK).Nüüd 2 päeva hiljem on tõusnud juba 70%!!! Käive pole kah just väga väike olnud. :S<br /><br />Mingit infot olen netis kah leidnud: <br /><br />www.nutripharma.com<br /><br />THIRD QUARTER 2006 RESULTS<br /><br />(Oslo, 16 November 2006) Nutri Pharma (OSE: NUT) today reports operating revenues of NOK 16.9 million and a loss of NOK 4.1 million for the third quarter of 2006. This compares to revenues of NOK 1.4 million and a loss of NOK 1.8 million in the third quarter of 2005. Operating costs in third quarter were NOK 20.8 million compared to NOK 3.0 million in Q3-2005. EBITDA in third quarter shows a deficit of NOK 2.4 million. Amortisation of intangible assets has been charged with NOK 1.5 million in the third quarter (NOK 0.4 million in Q3-2005). Net financial items are recorded with a deficit of TNOK 151 compared to a deficit of TNOK 82 in the same quarter the previous year.<br /><br />Total revenues decreased by 34% compared to the second quarter's revenues of MNOK 25.7. Out of the total sales of MNOK 16.9 in the third quarter, MNOK 15.8 were recorded in MIG (Russia/CIS) and MNOK 1.1 in the Nordic region.<br /><br />Nordic region<br />Royalty income in Q3-06 from the Nordic area increased by 8% compared to second quarter 2005. Total revenues recorded in Q3-05 were NOK 1.4 million of which NOK 1.0 million derived from the Nordic area and 0.4 million from MIG (Russia/CIS) prior to the acquisition of the company. Royalty revenues in the third quarter 2006 were NOK 1.1 million. <br /><br />A provision of NOK 1.2 million relating to the liquidation process of Nutri Pharma's two Danish subsidiaries has been released. The operating profit from the Nordic region was NOK 1.6 million compared to an operating loss of NOK 1.7 million i Q3-2005. Amortisation of Royalty and Patent rights has been expensed with NOK 0.4 million (Q3-2005: NOK 0.4 million). <br /><br />Russia/CIS<br />Compared to second quarter 2006 the revenues in Russia/CIS were reduced by 35%, and both sales of Nutri Pro and cosmetics products were reduced. MIG achieved a gross margin of 87% from sales in Q3, even after a stock provision of MNOK 0.8 million. The business segment Russia/CIS delivered a negative EBITDA of NOK 4.4 million. In Q3-2006 the variable proportion of MIGs costs were 77% of the revenues, covering cost of goods sold, commissions to distributors and service providers. A cost of MNOK 3 million for the annual Premium event in Moscow has been expensed in Q3-06.<br /><br />As from 1 October 2005 Nutri Pharma operates with two business segments; Nordic, with the existing royalty revenues, and Russia + CIS countries through the direct sales organisation of MIG. <br /><br />Consolidated Income statement (main figures) <br /><br />Q3 2006 Q3 2005 (Amounts in NOK 000) 9M 2006 9M 2005 FY 2005<br />16,921 1,367 Total revenue 65,142 3,579 25,345<br />20,876 3,043 Total operating expenses 71,127 13,862 35,088<br />-3,955 -1,676 Result of operations -5,985 -10,283 -9,743<br />-151 -82 Net Financial items -346 2 132<br />-4,106 -1,758 Profit/(loss) before taxes -6,331 -10,281 -9,611<br />- - Income tax expense - - -<br />-4,106 -1,758 Profit/(loss) for the period -6,331 -10,281 -9,611<br />-0.05 -0.02 EPS (NOK) -0.08 -0.14 -0.13<br /><br />Sorry kui liiga palju ülearust teksti tuli.Kas oskaksite kommenteerida,millest selline tõus?!!<br />Tänud!<br /><br />